Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...

A cardiovascular specialty hospital in north Texas decreased time to diagnosis for patients with cardiogenic shock by more ...

and indicated for the treatment of ongoing cardiogenic shock that occurs immediately (<48 hours) following acute myocardial infarction or open heart surgery or in the setting of cardiomyopathy ...

The patent filing expands upon data obtained from animal model testing and the istaroxime human clinical trials in acute heart failure (AHF) and early cardiogenic shock (ECS), including the latest ...

Progress in assessing cardiovascular risk and identifying early prevention opportunities, improvements in treating heart failure, new therapies for bleeding strokes, strategies for reducing the ...